and perhaps negotiations with national health services will also make it more cost-effective than Wegovy,” Alciati continued.

So, Zepbound is expected to take the lead in the obesity market if it hasn’t already done so.” Based on SURMOUNT-5 results released last month, Zepbound was more effective in promoting weight ...

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...

So, Zepbound is expected to take the lead in the obesity market if it hasn’t already done so.” Eli Lilly announced the results of its SURMOUNT-5 study back in December, which compared the impact of ...

I had been taking Zepbound for about six months when it clicked. My period — the monster that turned me from a functioning ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...